9 active not recruiting. 9 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 9 |
| Phase 1 | 4 | Active not recruiting 4 |
Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis CC-97540, Lymphodepletion Chemotherapy - Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 / Phase 2 | Active not recruiting | Marcela V. Maus, M.D.,Ph.D. | 12 | 2026-03-30 | 2026-09-10 |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA Rapcabtagene autoleucel, Active Comparator, Glucocorticoids - ANCA Associated Vasculitis (AAV) | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 126 | 2025-03-13 | 2026-09-04 |
| The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN) Telitacicept 160mg, Prednisone (and methylprednisolone), Cyclophosphamide - Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN) | Phase 1 / Phase 2 | Active not recruiting | Renmin Hospital of Wuhan University | 15 | 2024-10-10 | 2024-10-24 |
| Iptacopan in Patients With ANCA Associated Vasculitis Iptacopan, Placebo, Rituximab - Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 84 | 2024-08-05 | 2026-10-15 |
| Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis Tezepelumab, Placebo - EGPA - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 | Active not recruiting | Imperial College London | 42 | 2024-05-15 | 2026-04-29 |
| Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis NS-229, Placebo - Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome | Phase 2 | Active not recruiting | NS Pharma, Inc. | 45 | 2023-12-20 | 2026-05-26 |
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
| ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) Sparsentan - ANCA Associated Vasculitis, Cardiovascular Diseases | Phase 2 | Active not recruiting | University of Edinburgh | 32 | 2022-12-08 | 2026-08-26 |
| TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Trimethoprim Sulfamethoxazole - Granulomatosis With Polyangiitis, Wegener Granulomatosis | Phase 1 / Phase 2 | Active not recruiting | University of Pennsylvania | 8 | 2019-03-27 | 2026-09-25 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (6) · Granulomatosis with Polyangiitis (4) · Churg-Strauss Syndrome (3) · Microscopic Polyangiitis (3) · Vasculitis (2) · Cardiovascular Diseases (1) · Glomerulonephritis, IGA (1) · Glomerulonephritis, Membranous (1) · Kidney Diseases (1) · Lupus Nephritis (1)
Autoimmune Diseases (9) · Immune System Diseases (9) · Skin Diseases (9) · Skin Diseases, Vascular (9) · Skin and Connective Tissue Diseases (9) · Vascular Diseases (9) · Cardiovascular Diseases (8) · Vasculitis (7) · Lung Diseases (4) · Lung Diseases, Interstitial (4) · Respiratory Tract Diseases (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Brain Diseases (3) · Central Nervous System Diseases (3)
Cyclophosphamide (1) · Glucocorticoids (1) · Methylprednisolone (1) · Prednisone (1) · Rituximab (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · iptacopan (1) · sparsentan (1) · telitacicept (1) · tezepelumab (1)
Novartis Pharmaceuticals (2) · Alpine Immune Sciences, Inc. (1) · Imperial College London (1) · Marcela V. Maus, M.D.,Ph.D. (1) · NS Pharma, Inc. (1) · Renmin Hospital of Wuhan University (1) · University of Edinburgh (1) · University of Pennsylvania (1)
United States (6) · United Kingdom (5) · Australia (2) · Canada (2) · China (2) · France (2) · Germany (2) · Japan (2) · Spain (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Czechia (1) · Denmark (1)
Neeraj Dhaun (1) · Salman Siddiqui, MBBS (1) · Sebastian Unizony, MD (1)
2023 (1)